Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)

• Company Description    Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $82.62 Daily Weekly Monthly 20 Day Moving Average: 1,747,165 shares Shares Outstanding: 48.77 (millions) Market Capitalization: $4,029.05 (millions) Beta: 0.16 52 Week High: $151.02 52 Week Low: $13.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.87% -14.51% 12 Week -31.92% -33.78% Year To Date -17.16% -18.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2800 CAMPUS DRIVE SUITE 140 - MINNEAPOLIS,MN 55441 USA ph: 763-392-0123 fax: - None http://www.celcuity.com

• General Corporate Information    Officers Brian F. Sullivan - Chief Executive Officer and Chairman Vicky Hahne - Chief Financial Officer Richard E. Buller - Director Dave F. Dalvey - Director Leo T. Furcht - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15102K100 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 48.77 Most Recent Split Date: (:1) Beta: 0.16 Market Capitalization: $4,029.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 74.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -12.79% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -244.61 12/31/25 - -203.17 ROA 06/30/26 - - 03/31/26 - -50.22 12/31/25 - -52.68 Current Ratio 06/30/26 - - 03/31/26 - 12.31 12/31/25 - 10.55 Quick Ratio 06/30/26 - - 03/31/26 - 12.31 12/31/25 - 10.55 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.11 12/31/25 - 2.17 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 6.04 12/31/25 - 3.20 Debt-to-Capital 06/30/26 - - 03/31/26 - 85.80 12/31/25 - 76.19

Powered by Zacks Investment Research ©